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Abstract
Background: Immunohistochemical markers are often used to classify breast cancer into subtypes that are biologically
distinct and behave differently. The aim of this study was to estimate mortality for patients with the major subtypes of
breast cancer as classified using five immunohistochemical markers, to investigate patterns of mortality over time, and to
test for heterogeneity by subtype.
Methods and Findings: We pooled data from more than 10,000 cases of invasive breast cancer from 12 studies that had
collected information on hormone receptor status, human epidermal growth factor receptor-2 (HER2) status, and at least
one basal marker (cytokeratin [CK]5/6 or epidermal growth factor receptor [EGFR]) together with survival time data.
Tumours were classified as luminal and nonluminal tumours according to hormone receptor expression. These two groups
were further subdivided according to expression of HER2, and finally, the luminal and nonluminal HER2-negative tumours
were categorised according to expression of basal markers. Changes in mortality rates over time differed by subtype. In
women with luminal HER2-negative subtypes, mortality rates were constant over time, whereas mortality rates associated
with the luminal HER2-positive and nonluminal subtypes tended to peak within 5 y of diagnosis and then decline over time.
In the first 5 y after diagnosis the nonluminal tumours were associated with a poorer prognosis, but over longer follow-up
times the prognosis was poorer in the luminal subtypes, with the worst prognosis at 15 y being in the luminal HER2-positive
tumours. Basal marker expression distinguished the HER2-negative luminal and nonluminal tumours into different subtypes.
These patterns were independent of any systemic adjuvant therapy.
Conclusions: The six subtypes of breast cancer defined by expression of five markers show distinct behaviours with
important differences in short term and long term prognosis. Application of these markers in the clinical setting could have
the potential to improve the targeting of adjuvant chemotherapy to those most likely to benefit. The different patterns of
mortality over time also suggest important biological differences between the subtypes that may result in differences in
response to specific therapies, and that stratification of breast cancers by clinically relevant subtypes in clinical trials is
urgently required.
Please see later in the article for the Editors’ Summary.
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Breast cancer is a heterogeneous disease that can be classified
using a variety of clinical and pathological features. Classification
may help in prognostication and targeting of treatment to those
most likely to benefit. Currently, estrogen receptor (ER) status and
human epidermal growth factor receptor-2 (HER2) status are
routinely used as predictive markers to select specific adjuvant
therapies. Prognostic markers may also be used to target adjuvant
chemotherapy to those at highest risk of poor outcome—for
example, the risk prediction tool Adjuvant!Online (www.adjuvant.
org) uses prognostic markers to predict the likely absolute benefit
of postoperative hormonal and/or chemotherapy and is widely
used by oncologists to identify patients most likely to benefit from
adjuvant treatment.
Perou et al. identified four breast cancer subtypes on the basis of
gene-expression profiling of 39 invasive breast tumours and three
normal breast specimens [1]. There was one ER-positive (ER+/
luminal-like) and three ER-negative subtypes (basal-like, ERBB2+,
and normal-like). In addition to expressing the ER receptor,
luminal-like tumours expressed other genes that were characteristic
of luminal or glandular epithelial cells of origin. The basal-like
tumours expressed basal or myoepithelial markers, and none of the
basal tumours expressed ER. Similar to the basal-like tumours,
overexpressionof the ERBB2 oncogene was associated with low ER.
The normal-like subgroup was typified by high gene expression for
basal and low expression for luminal breast epithelium. A
subsequent gene expression analysis by Sorlie et al. of patterns in
78 breast cancers, three fibroadenomas, and four normal breast
tissues suggested that the luminal-like subtype could be further
separated into two subgroups: luminal A and luminal B [2]. The
molecular subtypes were reflected in differences in prognosis.
Overall and relapse-free survivals were most favourable for luminal
A tumours and least favourable for ERBB2+ and basal-like breast
cancers. The investigators also suggested that there may be a third
luminal subgroup, the luminal C tumours, but this has not been
supported by the subsequent analysis of an expanded dataset [3].
The classification of breast cancers into subgroups on the basis
of gene expression patterns in tumour tissue is often regarded as
the gold standard, but widespread use of gene-expression profiling
in either the clinical or the research setting remains limited. Lack
of widespread use of expression profiles is primarily due to the
expense and technical difficulty encountered when carrying out
high-throughput gene-expression profiling using paraffin-embed-
ded material. Moreover, the currently defined subtypes based on
expression profiling were determined through the study of
relatively small numbers of tumours and these subgroups may
not be definitive. Consequently there is interest in using
immunohistochemical (IHC) markers to classify tumours into
subtypes that are surrogates for those based on gene-expression
profiling [4].
Many investigators have used IHC to classify tumours but have
used different naming conventions. Generally a hierarchical
classification is used, with luminal and nonluminal tumours
defined as those tumours that express either ER or progesterone
receptor (PR) and those that do not. The luminal and nonluminal
groups can then be further subdivided according to HER2-
expression status to generate four subtypes, and these four
subtypes can each be categorised according to whether or not
they express a basal marker yielding a total of eight subtypes. The
mapping of these eight IHC subtypes onto the five subtypes based
on gene expression is not exact.
Luminal A tumours as defined by gene expression have, in
general, higher expression of ER-related genes and lower
expression of proliferative genes than luminal B tumours [5].
However, there are no established IHC markers for subdividing
the luminal subtypes into the same categories. Recently, it has
been suggested that the luminal B subtype is equivalent to those
that express either HER2 or the proliferation marker KI67 [6].
The nonluminal tumours are ER negative and PR negative and
are generally subdivided into three groups. The nonluminal,
HER2-positive tumours are the equivalent of the ERBB2-
overexpressing tumours. Tumours that do not express ER, PR,
or HER2—the triple negative phenotype (TNP) tumours—are
often regarded as equivalent to the basal subtype as they can be
easily identified with IHC markers that are currently used in
routine clinical use. However, not all TNP tumours express basal
cytokeratins (CKs), and within the TNP subtype, expression of
basal markers may reflect important clinical differences. Expres-
sion of either CK5/6 or epidermal growth factor receptor (EGFR)
has been shown to accurately identify basal-like tumours classified
using gene expression [7,8], and several published studies have
used these markers to subclassify the TNP tumours into a core
basal subgroup (CBP), which is equivalent to the basal-like from
expression profiling and the five negative phenotype (5NP: ER2,
PR2, HER22, CK5/62, and EGFR2). Although this hierar-
chical classification is commonly used, questions remain as to
whether these groups are biologically distinct and clinically
relevant. For example, it has been suggested that basal markers
can be used to classify the basal tumours independent of other
markers [9]. Cheang et al. reported a significantly poorer survival
in CBP tumours compared to the 5NP tumours [10], an
observation that supports the notion that the two are biologically
distinct types of the TNP tumours. This finding was not confirmed
by a smaller study with limited power to detect small differences
[11]. A third study reported that the prognostic significance of
CBP tumours was similar to that of the TNP tumours [12].
However, they did not explicitly compare the CBP and 5NP
subtypes.
Previously published studies have either compared the five
subtypes by using the luminal HER2-negative tumours as a
reference category to compare with the other four subtypes
[8,10,12,13], or they have compared the subtypes by restricting
the analysis to either luminal or nonluminal tumours [6,11].
Unanswered questions include whether the behaviour of luminal
HER2-positive tumours and the nonluminal HER2-positive
tumours are different, whether the behaviour of luminal basal-
positive tumours is different from that of the nonluminal basal-
positive tumours, and whether basal marker status is important in
the luminal, HER2-negative tumours.
The association between ER status and mortality is known to be
time dependent, with hazard ratios for ER-positive versus ER-
negative tumours being lower than one in the first years after
diagnosis and becoming higher than one after 7–10 y. Mortality in
women with ER-positive tumours remains fairly constant over
time, whereas the mortality in women with ER-negative tumours
is initially higher than that in women with ER-positive disease and
then falls to a lower rate after 7–10 y [14–16]. In addition,
Tischkowitz and colleagues reported that the prognostic effects of
both TNP and CBP tumours compared to luminal tumours tended
to diminish over time, whereas the effect of CK5 and other basal
markers, when considered alone, might increase with time [12].
Another study reported that the effects of the CBP were attenuated
over time [13]. Inspection of the Kaplan-Meier survival curves
published by Cheang et al. also suggest that the prognostic effects
of the CBP and 5NP subtypes are time dependent [10].
All the major subtypes apart from the luminal A tumours are
relatively infrequent, and only very large studies with prolonged
Breast Cancer Survival by IHC Subtype
PLoS Medicine | www.plosmedicine.org 3 May 2010 | Volume 7 | Issue 5 | e1000279follow-up have the power to study meaningful differences in
prognosis. The aim of this study was to pool individual data from
multiple breast cancer case series, in order to definitively establish
the relative survival of the major subtypes of breast cancer as
classified using five IHC markers, and to characterise their
prognostic effects over time.
Materials and Methods
Ethics Statement
All studies were approved by the relevant research ethics
committee or institutional review board. Participants in Amster-
dam Breast Cancer Study (ABCS), Helsinki Breast Cancer Study
(HEBCS), Jewish General Hospital (JGH), Mayo Clinic Breast
Cancer Study (MCBCS), Melbourne Collaborative Cohort Study
(MCCS), Polish Breast Cancer Study (PBCS), Sheffield Breast
Cancer Study (SBCS), and Study of Epidemiology and Risk
factors in Cancer Heredity (SEARCH) provided informed written
consent. Samples for British Columbia Cancer Agency (BCCA),
Nottingham Breast Cancer Case Series (NOBCS), University of
British Columbia (UBC), and Vancouver General Hospital (VGH)
were from legacy archival material and individual consent was not
obtained. All data were anonymised before being sent to the
coordinating centre for analysis.
Study Populations
The international breast cancer association consortium (BCAC)
comprises a large number of studies investigating the role of
common germline genetic variation in breast cancer susceptibility
[17]. In addition to data on germline genotype, many BCAC
studies have detailed pathological data on the breast cancer cases
linked to follow-up data. All BCAC studies that had collected IHC
data on ER, PR, HER2, and either EGFR or CK5/6 or both, in
addition to survival time data and data on tumour grade, size, and
nodal status were eligible for inclusion in this study. The
investigators of the three previously published studies with
equivalent data [10–12], were also invited to contribute their
data, as were the investigators of a fourth large breast cancer case
series that had taken part in a previous collaboration involving
other BCAC studies [18]. All studies provided data on age at
diagnosis, vital status, breast cancer-specific mortality, time
between diagnosis and ascertainment, follow-up time, tumour
grade (low, intermediate, and high), tumour size (,2 cm, 2–
4.9 cm, $5 cm) and node status (positive or negative). In total, 12
studies from Europe, North America, and Australia contributed
data on 10,159 cases with complete data [7,9,10,12,18–29]. Nine
studies also provided data on whether or not the patient had been
treated with adjuvant hormonal therapy or adjuvant chemother-
apy. These data were available for a subset of 8,171 and 8,061
cases, respectively. The studies are described in Table 1.
Immunohistochemistry and Tumour Classification
Data for these antibodies were either derived from IHC
performed in a research setting or collated from patient records
by the individual groups. The methods used by each study for each
marker are shown in Table S1. The cases were grouped into
subtypes on the basis of their protein expression profile (Figure 1).
Luminal tumours were those with positive staining for ER or PR.
Luminal tumours were subdivided according to HER2 status into
luminal 1 (HER2-negative), which is broadly equivalent to the
luminal A tumours defined by gene expression, and luminal 2
(HER2-positive) tumours. The luminal 2 tumours are a subset of
the luminal B tumours because some of the tumours classified as
luminal 1 would be expected to express proliferative markers and
thus be misclassified luminal B tumours. The nonluminal tumours
were those that were negative for both ER and PR. These were
subdivided by HER2 expression status into the nonluminal
HER2-positive tumours and the TNP tumours. The TNP tumours
were further subdivided into the CBP tumours (either CK5/6 or
EGFR positive) and the 5NP tumours (CK5/6-negative and
EGFR-negative). Four studies did not provide data for EGFR, and
for these studies the 5NP tumours were those that were negative
for ER, PR, HER2, and CK5/6. A small number of 5NP tumours
from these studies will thus be misclassified core basal tumours.
The tumours classified as luminal 1 were also further subdivided
according to expression of basal markers into luminal 1, basal
marker negative and luminal 1, basal marker positive.
Statistical Analysis
The association between each prognostic marker and subtype
and all-cause mortality after diagnosis was investigated using Cox
regression stratified by study and adjusted for age at diagnosis,
grade, node status, and size of tumour. Ordinal categories of
tumour grade and size were treated as continuous variables in all
analyses. Age at diagnosis was treated as a categorical variable
(,40, 40–49, 50–59, and $60 y). In several studies the cases were
ascertained after diagnosis (prevalent cases), and this was allowed
for in the analysis by setting ‘‘time at risk’’ from the date of
diagnosis and ‘‘time under observation’’ on date of study entry.
This step produces an unbiased estimate of the hazard ratio
provided the proportional hazards assumption is correct [16].
Follow-up was censored on the date of death from any cause, or, if
death did not occur, on date last known alive or at 15 y after
diagnosis, whichever came first. The Cox proportional hazards
model assumes that the hazard ratio is constant over time. This
assumption is known to be violated for ER [14–16] and over
prolonged follow-up is also likely to be violated for other
predictors. We therefore carried out a conditional relative survival
analysis by splitting follow-up time into five different periods—0–
2, 2–4, 4–6, 6–10, and 10–15 y after diagnosis—and deriving Cox
models separately for each period. The Cox proportional hazards
assumption was checked for each study period by visual inspection
of the standard log-log plots. A test for heterogeneity of the study-
specific hazard ratios was carried out using the Mantel-Haenszel
method. Kaplan-Meier cumulative survival plots were adjusted for
study, age group, tumour grade, tumour size, and node status. In
order to provide an overall test of association to compare survival
time across all 15 y of follow-up we used multivariate Cox
regression models in which the prognostic factors were treated as
time-varying covariates. In these models the log hazard ratio varies
as a function of the natural logarithm of follow-up time. Models
with and without the covariates of interest were then compared
using likelihood ratio tests. All analyses were performed in
Intercooled Stata, version 10 (Stata Corp).
Results
Eight studies provided data on ER, PR, HER2, CK5/6, and
EGFR with a further four studies providing data on ER, PR, HER2,
and CK5/6, but not EGFR. Based on these data, there were 10,159
subjects that could be classified into one of the five major breast
subtypes. There were 3,181 deaths in 85,799 person-years of follow-
up, with 1,975 deaths from breast cancer. The multivariate, period-
specific hazard ratios for age (in four categories), tumour grade,
tumour size, node status, and the IHC markers are given in Table 2.
These data show that the hazard ratios for all variables except age at
diagnosis attenuate over time, and that for ER, PR, HER2, CK5/6,
EGFR, and grade the effect changes direction with time. The time-
Breast Cancer Survival by IHC Subtype
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There was little difference in the hazard ratios for all-cause mortality
and breast cancer-specific mortality, except for in the youngest and
oldest age groups (Figures S1 and S2). Breast cancer-specific hazard
ratios tended to be higher for women diagnosed under the age of
40 y (reference age at diagnosis 50–59 y). In contrast, for age at
diagnosis $60 y, all-cause mortality hazard ratios were greater, as
might be expected because of the impact of mortality from other
causes.
There were 7,882 luminal tumours (78% of total). Of these,
7,243 (92%) were luminal 1 and 639 (8%) were luminal 2. There
were 632 tumours of the nonluminal HER2-positive subtype (6%
of total), and 1,645 TNP tumours (16% of total). Of the TNP
tumours, 962 were CBP (58%) and 683 basal-negative tumours
(42%). The number of tumours by the five major subtypes for each
study are shown in Table 3. In addition to the five main subtypes,
we subdivided the luminal 1 tumours according to expression of
basal markers, with 562 (8%) being basal marker positive and
6,119 (92%) being basal marker negative (Table S2 shows the
luminal 1 subgroups by study). Table 4 shows the characteristics of
the five major breast cancer subtypes by age at diagnosis, tumour
grade, tumour size, and node status.
The hazard ratios over time for the five subtypes of breast
cancer, stratified by study and adjusted for grade, tumour size, and
node status, are shown in Figure 2. There was little evidence for
heterogeneity of effects by study for these hazard ratios except for
the 5NP tumours (Table S3). Figure 2 shows that, compared to the
luminal 1 tumours, luminal 2 tumours are associated with a
slightly poorer prognosis in the first few years after diagnosis, but
that the difference reduces with time, and by 8 y after diagnosis
there is no difference between the two. In contrast the mortality for
women with the HER2-enriched and both types of TNP tumours
(CBP and 5NP) is substantially greater than that for women with
the luminal 1 tumours immediately after diagnosis, but the
difference declines rapidly and reverses at 5–10 y after diagnosis.
These patterns reflect the time-dependent changes in mortality
rates in the different subgroups (Figure S3). Within the TNP
subgroup, the women with CBP tumours have a slightly poorer
prognosis than women with the 5NP tumours. This difference
declines slightly over time and by 8 y after diagnosis, no difference
is observed. A similar pattern is seen for the luminal 1, basal-
positive tumours when compared to the luminal 1, basal-negative
tumours. We repeated the analyses using breast cancer-specific
mortality as the end point (Figure S4). The hazard ratio estimates
Table 1. Description of participating studies.
Study Country
Case
Ascertainment Case Definition
Age
Range (y) References
ABCS The Netherlands Hospital-based All cases of operable, invasive cancer diagnosed from 1974 to 1994 in
four Dutch hospitals. Familial non-BRCA1/2 cases ,50 from the Clinical
Genetic Centre at The Netherlands Cancer Institute
23–50 [19]
BCCA Canada Hospital-based Women diagnosed with invasive breast cancer between 1986 to 1992 and
identified through the British Columbia Cancer Agency
23–89 [7,10]
HEBCS Finland Hospital-based (1) Consecutive cases (883) from the Department of Oncology, Helsinki
University Central Hospital 1997–1998 and 2000; (2) Consecutive cases (986)
from the Department of Surgery, Helsinki University Central Hospital 2001–2004;
(3) Familial breast cancer patients (536) from the Helsinki University Central
Hospital, Departments of Oncology and Clinical Genetics (1995–)
22–96 [20–22]
JGH Canada Hospital-based Ashkenazi Jewish women diagnosed with nonmetastatic, invasive breast
cancer at Jewish General Hospital, Montreal between 1980 and 1995
26–66 [12]
MCBCS USA Hospital-based Incident cases residing in six states (Minnesota, Wisconsin, Iowa, Illinois,
North Dakota, South Dakota) seen at the Mayo Clinic in Rochester,
Minnesota from 2002–2005
22–89 [23]
MCCS Australia Cohort Incident cases diagnosed within the Melbourne Collaborative Cohort Study during
the follow-up from baseline (1990–1994) to 2004 of the 24,469 participating women
30–82 [24]
NOBCS UK Hospital-based Primary operable breast carcinoma patients presenting from 1986 to 1998
and entered into the Nottingham Tenovus Primary Breast Carcinoma Series.
26–93 [9]
PBCS Poland Population-based Incident cases from 2000–2003 identified through a rapid identification system in
participating hospitals covering ,90% of all eligible cases; periodic check against
the cancer registries in Warsaw and Ło ´dz ´ to assure complete identification of cases
27–75 [25]
SBCS UK Hospital-based Women with pathologically confirmed breast cancer recruited from surgical
outpatient clinics at the Royal Hallamshire Hospital, Sheffield, 1998–2002; cases
are a mixture of prevalent and incident disease
29–93 [26,27]
SEARCH UK Population-based Two groups of cases identified through East Anglian Cancer Registry: (1)
prevalent cases diagnosed age ,55 y from 1991–1996 and alive when study
started in 1996; (2) incident cases diagnosed age ,70 y diagnosed after 1996
23–69 [18]
UBCBCT Canada Hospital-based Women with stage I to III breast cancer who participated in four different
British Columbia Cancer Agency clinical trials between 1970 and 1990
and all received chemotherapy
22–90 [28,29]
VGH Canada Hospital-based Women with primary breast cancer who underwent surgery at Vancouver
General Hospital 1975–1995
28–91 [12]
ABCS, Amsterdam Breast Cancer Study; BCCA, British Columbia Cancer Agency; HEBCS, Helsinki Breast Cancer Study; JGH, Jewish General Hospital; MCBCS, Mayo Clinic Breast
Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NOBCS, Nottingham Breast Cancer Case Series; PBCS, Polish Breast Cancer Study; SBCS, Sheffield Breast Cancer
Study; SEARCH, Study of Epidemiology and Risk factors in Cancer Heredity; UBCBCT, University of British Columbia Breast Cancer Trials; VGH, Vancouver General Hospital.
doi:10.1371/journal.pmed.1000279.t001
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all-cause mortality hazard ratios, but the confidence intervals were
somewhat wider.
The Kaplan-Meier cumulative survival for the three luminal
subtypes adjusted for study, grade, tumour size, and node status is
shown in Figure 3A. This result shows that the cumulative survival
for the luminal 1 subtypes declines almost linearly over time, which
is compatible with a constant mortality rate. In contrast, the
mortality rate in women with the luminal 2 tumours tends to flatten
out over time as the high mortality in the first few years after
diagnosis declines. It also clearly shows the poorer prognosis for the
luminal 1 tumours that are basal marker positive. The survival
curves associated with nonluminal HER2-positive, CBP, and 5NP
tumours all show a similar pattern to that of the luminal 2 tumours
(Figure 3B). There were significant differences in prognosis between
all pairs of subtypes apart from the nonluminal HER2-positive
tumours compared with the CBP tumours (Table S4). Of particular
note is the difference between the CBP and 5NP tumours
(p=0.0008). The luminal, HER2-positive tumours and the
nonluminal, HER2-positive tumours are two distinct subgroups,
with the nonluminal tumours having a poorer prognosis
(p,0.0001), and the CBP tumours having a poorer prognosis than
the luminal, basal-positive tumours (p,0.0001). These differences
did not depend on whether or not the patient had been treated with
eitheradjuvanthormonetherapyoradjuvantchemotherapy(Figure
S5). In contrast, the basal markers seem to have no prognostic
significance within the HER2 positive subtypes of disease (p=0.85).
The luminal, HER2-positive tumours and the nonluminal,
HER2-positive tumours represent two distinct subgroups, as do
the ER-positive/negative tumours that are basal positive. In both
cases the ER-negative tumours have a poorer prognosis in the first
few years after diagnosis, but after 5 to 10 y it is the ER-positive
tumours that have the poorer outcome (Figure S6). In contrast, the
basal markers seem to have no prognostic significance within the
HER2-positive subtypes of disease (unpublished data).
Data on the association between the major subtypes and
prognosis have previously been published for three of the studies
included in this analysis—BCCA, JGH, and VGH—and it is
possible that the effect estimates that we report here are subject to
publication bias. We therefore repeated all the analyses after
excluding the data for these three studies but there was little
difference in the results (see Figure S7).
Discussion
We evaluated the prognostic significance of five previously
described major subtypes of breast cancer that were classified
using five IHC markers. To our knowledge, this study represents
one of the largest datasets analysed for prognosis research in breast
cancer using IHC markers. Our data confirm the observations of
others that the pattern of survival in ER-positive tumours is
qualitatively different to that in ER-negative tumours. In ER-
positive tumours, the mortality rate is approximately constant over
time since diagnosis, whereas the mortality rate associated with
ER-negative disease is initially high and then progressively declines
over time. However, the pattern of mortality rates associated with
the HER2-positive subgroup of ER-positive tumours (luminal 2) is
similar to those of the nonluminal subtypes (Figure 3A).
Berry et al. suggest [14] that the pattern of mortality after
diagnosis associated with ER-positive tumours is mainly an effect
of treatment with adjuvant hormone therapy and that the pattern
of mortality in women not treated with adjuvant hormone therapy
is similar to that in women with ER-negative disease. The pattern
of mortality in women with luminal 1 tumours and treated with
adjuvant hormone therapy was similar to those who did not
receive hormone therapy (Figure S3). This result implies that the
time-dependent effects we observed are not simply the result of
adjuvant hormone therapy in a subset of the women with ER-
positive tumours. Few of the participants with HER2-positive
tumours in this study would have been treated with trastuzumab
and so the prognosis in women with these tumours would not
Figure 1. Classification of breast cancer subtypes according to IHC marker profile.
doi:10.1371/journal.pmed.1000279.g001
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survival patterns reflect the underlying molecular heterogeneity of
breast cancer. We have hypothesized that this heterogeneous
biology reflects the fact that breast cancers can initiate in different
cell types, either breast epithelial stem cells or their progeny
(transit amplifying cells or committed differentiated cells) [30].
Furthermore the recognition of the subtype-specific differences in
short-term and long-term prognosis will inevitably lead to tailored
follow-up programmes after completion of primary therapy.
Our data confirm the view that the TNP is not a good proxy for
the CBP because the CBP and 5NP tumours are biologically
distinct and show different behaviours. The CBP tumours are
clearly associated with a poorer prognosis than the 5NP tumours.
Currently, chemotherapy remains the only systemic treatment
option available for patients with triple negative (CBP and 5NP)
tumours. A number of small studies have shown that basal-like
cancers defined through gene-expression profiling or immuno-
phenotyping are responsive to chemotherapy regimes [31–33]. In
addition, the expression of core basal markers such as EGFR, may
lead to the application of targeted therapies, with EGFR inhibitors
currently under investigation for use in basal-like breast cancers.
We have also shown that the expression of basal markers in ER-
positive tumours is associated with a poorer prognosis, suggesting
that the luminal 1 tumours represent two distinct subtypes, both of
Table 3. Number of tumours by subtype and study.
Study Luminal 1 Luminal 2 Nonluminal HER2+ CBP 5NP Total
n Percent n Percent n Percent n Percent n Percent
ABCS 497 67 64 9 51 7 60 8 68 9 740
BCCA 2,378 71 206 6 238 7 317 9 209 6 3,348
HEBCS 169 72 25 11 8 3 21 9 13 6 236
JGH 160 77 18 9 5 2 21 10 3 1 207
MCBCS 219 86 24 9 4 2 8 3 1 ,12 5 6
MCCS 2 7 67 2 2 26 3 0 8 3 71 0 1 74 3 8 2
NOBCS 1,051 71 44 3 71 5 196 13 108 7 1,470
PBCS 694 69 35 3 67 7 137 14 75 7 1,008
SBCS 206 77 16 6 10 4 14 5 21 8 267
SEARCH 1,247 76 121 7 71 4 112 7 83 5 1,634
UBC 154 42 53 15 62 17 15 4 81 22 365
VGH 1 9 27 8 1 14 1 5 6 2 41 0 4 2 2 4 6
Total 7,243 71 639 6 632 6 962 9 683 7 10,159
ABCS, Amsterdam Breast Cancer Study; BCCA, British Columbia Cancer Agency; HEBCS, Helsinki Breast Cancer Study; JGH, Jewish General Hospital; MCBCS, Mayo Clinic
Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NOBCS, Nottingham Breast Cancer Case Series; PBCS, Polish Breast Cancer Study; SBCS, Sheffield
Breast Cancer Study; SEARCH, Study of Epidemiology and Risk factors in Cancer Heredity; UBCBCT, University of British Columbia Breast Cancer Trials; VGH, Vancouver
General Hospital.
doi:10.1371/journal.pmed.1000279.t003
Table 2. Multivariate period-specific all-cause mortality hazard ratios (95% CI).
Variable Time after Diagnosis
0–2 y 2–4 y 4–6 y 6–10 y 10–15 y
Age at diagnosis (y)
,40 0.69 (0.49–0.98) 1.09 (0.87–1.37) 1.14 (0.84–1.55) 0.83 (0.62–1.12) 0.68 (0.44–1.05)
40–49 0.63 (0.48–0.84) 0.77 (0.64–0.93) 0.83 (0.65–1.06) 0.66 (0.53–0.82) 0.51 (0.38–0.68)
50–59 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
$60 1.74 (1.36–2.22) 1.26 (1.04–1.52) 1.64 (1.31–2.06) 1.79 (1.49–2.14) 2.05 (1.63–2.58)
Grade
a 1.51 (1.24–1.84) 1.81 (1.59–2.08) 1.37 (1.18–1.60) 1.14 (1.01–1.29) 0.97 (0.83–1.13)
Node positive 2.64 (2.12–3.27) 2.42 (2.09–2.82) 1.86 (1.55–2.23) 1.56 (1.35–1.82) 1.40 (1.15–1.70)
Tumour size
a 1.67 (1.42–1.97) 1.47 (1.31–1.66) 1.43 (1.23–1.66) 1.37 (1.20–1.56) 1.30 (1.09–1.55)
ER positive 0.55 (0.42–0.71) 0.76 (0.63–0.91) 1.31 (1.02–1.68) 1.63 (1.29–2.07) 1.24 (0.91–1.69)
PR positive 0.36 (0.27–0.47) 0.62 (0.52–0.74) 0.74 (0.6–0.91) 1.04 (0.87–1.23) 1.16 (0.92–1.46)
HER2 positive 1.21 (0.95–1.52) 1.50 (1.27–1.78) 1.55 (1.23–1.96) 1.35 (1.07–1.69) 0.96 (0.67–1.37)
Basal marker positive 1.33 (1.06–1.68) 1.21 (1.01–1.44) 1.38 (1.08–1.78) 1.06 (0.83–1.35) 0.83 (0.59–1.17)
All analyses are stratified by study.
aGrade and tumour size are ordinal variables treated as continuous, giving hazard ratios per unit increase in score.
doi:10.1371/journal.pmed.1000279.t002
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prognostic model based on the six subtypes defined by five IHC
markers fits significantly better than a model based on three
subtypes—ER-positive or PR-positive and HER2-negative,
HER2-positive, and triple-negative tumours—defined by the three
markers currently in standard clinical practice (likelihood ratio
chisq=54.4, 3 degrees of freedom [df], p,0.0001).
One remaining question is whether the 5NP tumours represent
a distinct subtype or are just other subtypes that have been
misclassified because of assay failure. However, given the pattern
of mortality rates over time since diagnosis (Figure S3), it seems
unlikely that many of the 5NP tumours are misclassified luminal
tumours. If the 5NP tumours were misclassified nonluminal
HER2-positive or CBP tumours, we would expect the survival
associated with them to be intermediate, whereas the 5NP
tumours have a better prognosis than both the other nonluminal
subtypes. Furthermore, the prognosis associated with the 5NP is
different from each of the other five subtypes and is also different
from all the other subtypes combined. Thus it seems likely that the
majority of 5NP tumours represent a true distinct subtype, with a
small, but unknown, proportion representing misclassification of
the other subtypes, Until a marker to positively identify the
genuine 5NP subtype has been identified, it will not be possible to
separate these two sets of tumours.
Our study has several limitations. IHC was carried out in
different laboratories using different methods for both staining and
scoring and, as a result, some misclassification of tumour subtypes
is inevitable. However, it is likely that such error is random with
respect to patient outcome. For the analyses of breast cancer-
specific mortality, cause of death was obtained from the underlying
cause of death as reported on death certificates and may thus be
associated with some error. However, any error in ascertaining
cause of death is likely to be random with respect to tumour
characteristics. Thus, measurement error of either breast cancer
subtype, as a result of interlaboratory variability or outcome, is, if
anything, likely to result in an underestimate of any true
differences between subtypes. The fact that we have found clear
differences in subtypes classified by IHC analyses that were carried
out in different laboratories, and would therefore be subject to
interlaboratory assay result variability, suggests that the markers
are robust to interlaboratory variation in their application and
therefore suitable for use in routine clinical practice.
There is also some nonrandom error as the luminal 1 tumours
that express proliferation markers are likely to behave more like
luminal 2 tumours [6]. As the luminal 1 tumours were used as the
reference category, this misclassification is likely to lead to an
underestimation in the true difference between luminal 1 and the
other subtypes. Similarly, some of the 768 5NP tumours will be
misclassified CBP tumours because data on EGFR were missing.
Assuming these data were missing at random, approximately 25 of
the 5NP tumours may represent misclassified CBP tumours.
However, when the definition of 5NP tumours was restricted to
those that were negative for both CK5/6 and EGFR, there was
little difference in the hazard ratio estimates (unpublished data.
Finally, the effects may also be underestimated because of the
nonrandom use of adjuvant chemotherapy. The more aggressive
subtypes are more likely to have been treated with chemotherapy,
which would result in a reduction in the difference between these
groups and the better prognosis subtypes.
Data from 12 different studies were used in this analysis. These
studies represent different ethnic groups from different regions of
the world as well as differences in case ascertainment. Furthermore
there were differences in the way that pathology samples were
handled, stained, and scored, and the degree of misclassification
Table 4. Characteristics of breast cancer subtypes by age at diagnosis, tumour grade, tumour size, and node status.
Breast Cancer Subtype
Characteristics Luminal 1 Luminal 2 HER2-enriched CBP 5NP Total n Percent
n Percent n Percent n Percent n Percent n Percent
Vital status at censoring
Alive 5,242 72 369 58 333 53 590 61 444 65 6,978 69
Dead 2,001 28 270 42 299 47 372 39 239 35 3,181 31
Age group (y)
,40 457 6 74 12 80 13 165 17 90 13 866 9
40–49 1,960 27 215 34 190 30 286 30 237 35 2,888 28
50–59 3,142 43 233 36 268 42 377 39 238 35 4,258 42
$60 1,684 23 117 18 94 15 134 14 118 17 2,147 21
Tumour grade
1 1,493 21 41 6 20 2 15 3 40 6 1,609 16
2 3,645 50 239 37 146 23 129 13 174 25 4,333 42
3 2,105 29 359 56 466 73 818 85 469 69 4,217 42
Node status
Negative 4,229 58 278 44 267 42 577 60 367 54 5,718 56
Positive 3,014 42 361 56 365 58 385 40 316 46 4,441 44
Tumour size
,2 cm 4,441 61 300 47 272 43 442 46 296 43 5,751 56
2–4.9 cm 2,580 36 306 48 318 50 468 49 336 49 4,008 39
$5 c m 2 2 2 33 3 54 2 75 2 55 1 74 0 2 4
doi:10.1371/journal.pmed.1000279.t004
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may weaken the observed associations, and limit the specificity of
the conclusions drawn. Nevertheless, the clear differences between
the subtypes of breast cancer that we identified, despite the
presence of heterogeneity, make the results robust and broaden
their generalisability.
In conclusion, we have confirmed that six breast cancer
subtypes can be robustly classified using five IHC markers. These
subtypes behave differently with specific patterns of mortality over
time since diagnosis. These characteristics are independent of
other clinico-pathological markers of prognosis and independent
of systemic therapy received. The classification based on these
markers is robust to multiple sources of heterogeneity between
studies suggesting that they are suitable for use in routine clinical
practice. The incorporation of these markers into prognostic tools
such as Adjuvant!Online and the Nottingham Prognostic Index
currently used in clinical practice or tools such as PREDICT [34],
which was recently developed to enable the incorporation of novel
prognostic biomarkers, may be warranted. It is plausible that these
markers are predictive and that different subtypes respond
differently to specific treatments, and the evaluation of subtype-
specific responses in the context of clinical trials of specific
treatments is urgently required. Given that these subtypes can
easily be defined using robust IHC markers in archival material,
Figure 2. Period-specific hazard ratios (all-cause mortality) for major breast cancer subtypes. All hazard ratios are stratified by study and
adjusted for tumour grade, tumour size, and node status.
doi:10.1371/journal.pmed.1000279.g002
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data.
Supporting Information
Figure S1 Comparison of multivariate, period-specific hazard
ratios for age group, tumour grade, and node status based on all-
cause and breast-specific mortality. Left-hand panel are results for
all-cause mortality and right-hand panels results for breast-specific
mortality. Tumour size was treated as an ordinal variable in the
Cox regression models and so the hazard ratios represent the
hazard ratio for a unit change in the variable.
Found at: doi:10.1371/journal.pmed.1000279.s001 (1.29 MB
EPS)
Figure S2 Comparison of multivariate, period-specific hazard
ratios for tumour size, ER, PR, HER2, and basal marker status
based on all-cause and breast-specific mortality. Left-hand panel
are results for all cause mortality and right-hand panels results for
breast specific mortality. Tumour size was treated as ordinal
variables in the Cox regression models and so the hazard ratios
represent the hazard ratio for a unit change in the variable.
Found at: doi:10.1371/journal.pmed.1000279.s002 (1.26 MB
EPS)
Figure S3 Breast cancer-specific mortality by subtype and time
since diagnosis.
Found at: doi:10.1371/journal.pmed.1000279.s003 (0.65 MB
EPS)
Figure S4 Period-specific hazard ratios (breast-specific mortal-
ity) for major breast cancer subtypes. All hazard ratios are
stratified by study and adjusted for tumour grade, tumour size, and
node status.
Found at: doi:10.1371/journal.pmed.1000279.s004 (1.01 MB
EPS)
Figure S5 Kaplan-Meier cumulative survival in luminal and
nonluminal tumours by subtype and by treatment with adjuvant
hormone therapy and adjuvant chemotherapy. All curves are
adjusted for age at diagnosis, tumour grade, tumour size, node
status, and study.
Found at: doi:10.1371/journal.pmed.1000279.s005 (2.18 MB
EPS)
Figure S6 Period-specific hazard ratios for ER-negative versus
ER-positive disease stratified by HER2 status and basal marker
status. All hazard ratios are adjusted for age at diagnosis, tumour
grade, tumour size, and node status and stratified by study.
Found at: doi:10.1371/journal.pmed.1000279.s006 (0.81 MB
EPS)
Figure S7 Comparison of period- and subtype-specific hazard
ratios (all-cause mortality) for all data and for subset of data after
excluding published studies. Left-hand panels show results based
on all data (as shown in Figure 1) and right-hand panels show
equivalent hazard ratios after exclusion of data from BCCA, JGH,
and VGH.
Found at: doi:10.1371/journal.pmed.1000279.s007 (1.24 MB
EPS)
Table S1 Methods used for IHC analysis by study.
Found at: doi:10.1371/journal.pmed.1000279.s008 (0.10 MB
DOC)
Table S2 Classification of luminal 1 tumours by basal marker
expression.
Found at: doi:10.1371/journal.pmed.1000279.s009 (0.04 MB
DOC)
Table S3 p-Values for test for heterogeneity of period-specific
hazard ratio estimates (compared to luminal 1 tumours) by study.
Found at: doi:10.1371/journal.pmed.1000279.s010 (0.03 MB
DOC)
Table S4 Likelihood ratio test statistic (2 degrees of freedom)
and p-value for comparison of 15-y all-cause mortality between
each subtype pair.
Found at: doi:10.1371/journal.pmed.1000279.s011 (0.04 MB
DOC)
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Background. Each year, more than one million women
discover they have breast cancer. Breast cancer begins when
cells in the breast’s milk-producing glands or in the tubes
(ducts) that take milk to the nipples acquire genetic changes
that allow them to divide uncontrollably and to move
around the body (metastasize). The uncontrolled cell division
leads to the formation of a lump that can be detected by
mammography (a breast X-ray) or by manual breast
examination. Breast cancer is treated by surgical removal of
the lump or, if the cancer has started to spread, by removal
of the whole breast (mastectomy). Surgery is usually
followed by radiotherapy or chemotherapy. These
‘‘adjuvant’’ therapies are designed to kill any remaining
cancer cells but can make women very ill. Generally
speaking, the outlook (prognosis) for women with breast
cancer is good. In the United States, for example, nearly 90%
of affected women are still alive five years after their
diagnosis.
Why Was This Study Done? Because there are several
types of cells in the milk ducts and glands, there are several
subtypes of breast cancer. Luminal tumors, for example,
begin in the cells that line the ducts and glands and usually
grow slowly; basal-type tumors arise in deeper layers of the
ducts and glands and tend to grow quickly. Clinicians need
to distinguish between different breast cancer subtypes so
that they can give women a realistic prognosis and can give
adjuvant treatments to those women who are most likely to
benefit. One way to distinguish between different subtypes
is to stain breast cancer samples using antibodies (immune
system proteins) that recognize particular proteins
(antigens). This ‘‘immunohistochemical’’ approach can
identify several breast cancer subtypes but its prognostic
value and the best way to classify breast tumors remains
unclear. In this study, the researchers investigate the survival
over time of women with six major subtypes of breast cancer
classified using five immunohistochemical markers: the
estrogen receptor and the progesterone receptor (two
hormone receptors expressed by luminal cells), the human
epidermal growth factors receptor-2 (HER2, a protein marker
used to select specific adjuvant therapies), and CK5/6 and
EGFR (proteins expressed by basal cells).
What Did the Researchers Do and Find? The researchers
pooled data on survival time and on the expression of the
five immunohistochemical markers from more than 10,000
cases of breast cancer from 12 studies. They then divided the
tumors into six subtypes on the basis of their marker
expression: luminal (hormone receptor-positive), HER2-
positive tumors; luminal, HER2-negative, basal marker-
positive tumors; luminal, HER2-negative, basal marker-
negative tumors; nonluminal (hormone receptor-negative),
HER2-positive tumors; nonluminal, HER2-negative, basal
marker-positive tumors; and nonluminal, HER2-negative,
basal marker-negative tumors. In the first five years after
diagnosis, women with nonluminal tumor subtypes had the
worst prognosis but at 15 years after diagnosis, women with
luminal HER2-positive tumors had the worst prognosis.
Furthermore, death rates (the percentage of affected
women dying each year) differed by subtype over time.
Thus, women with the two luminal HER2-negative subtypes
were as likely to die soon after diagnosis as at later times
whereas the death rates associated with nonluminal
subtypes peaked within five years of diagnosis and then
declined.
What Do These Findings Mean? These and other
findings indicate that the six subtypes of breast cancer
defined by the expression of five immunohistochemical
markers have distinct biological characteristics that are
associated with important differences in short-term and
long-term outcomes. Because different laboratories
measured the immunohistochemical markers using
different methods, it is possible that some of the tumors
included in this study were misclassified. However, the
finding of clear differences in the behavior of the
immunochemically classified subtypes suggests that the
use of the five markers for tumor classification might be
robust enough for routine clinical practice. The application of
these markers in the clinical setting, suggest the researchers,
could improve the targeting of adjuvant therapies to those
women most likely to benefit. Furthermore, note the
researchers, these findings strongly suggest that subtype-
specific responses should be evaluated in future clinical trials
of treatments for breast cancer.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000279.
N This study is further discussed in a PLoS Medicine
Perspective by Stefan Ambs
N The US National Cancer Institute provides detailed
information for patients and health professionals on all
aspects of breast cancer (in English and Spanish)
N The American Cancer Society has a detailed guide to
breast cancer, which includes information on the immu-
nochemical classification of breast cancer subtypes
N The UK charities MacMillan Cancer Support and Cancer
Research UK also provide detailed information about
breast cancer
N The MedlinePlus Encyclopedia provides information for
patients about breast cancer; Medline Plus provides links
to many other breast cancer resources (in English and
Spanish)
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